-49%

est. 2Y upside i

HealthcareSeries D+

Rank

#3501

Sector

Neurotechnology / Healthcare

Est. Liquidity

~5Y

Data Quality

Data: Medium

Neuralink presents a high-risk, potentially high-reward equity opportunity.

Last updated: March 10, 2026

Bull (20%)+100%

Neuralink successfully navigates full FDA commercial approval for its Telepathy and Blindsight devices, achieving high-volume automated production by 2026 and exceeding its 2031 revenue target of $1 billion. This market leadership and rapid adoption in disabilities and vision restoration segments drive the valuation to $40 billion, a 2x from the current secondary market valuation.

Base (40%)+25%

Neuralink achieves initial FDA commercial approval for Telepathy, but faces slower-than-projected adoption and intense competition from Synchron and Science Corp. Revenue growth is steady but below aggressive targets, reaching approximately $300-500 million by 2031. The company's valuation modestly increases to $25 billion, reflecting partial success and continued R&D investment.

Bear (40%)-40%

Significant regulatory delays, persistent safety concerns (e.g., thread retraction issues), or stronger-than-anticipated competition from less invasive BCI solutions like Synchron's Stentrode severely hamper commercialization. Public backlash or ethical concerns also limit market acceptance. Revenue remains minimal, leading to a down round or acquisition at a significantly reduced valuation of $12 billion, wiping out a substantial portion of common stock value.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Funding Intensity

13%

Investors hold $1.3 billion in liquidation preferences ahead of common stock, representing 6.5% of the current secondary market valuation.

Dilution Risk

moderate

As a capital-intensive, late-stage company with a long path to profitability, further funding rounds are likely before an IPO, posing a moderate risk of additional dilution.

Secondary Liquidity

active

An active secondary market exists for Neuralink shares, with demand currently outstripping supply, allowing accredited investors to buy and sell shares [8].

Other — 71 roles

View all 71 open roles at Neuralink →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Neuralink's data — designed to show you've done your homework.

  • 1

    “Given Synchron's less invasive approach and advanced clinical trial stage, how does Neuralink plan to differentiate and capture market share in the motor function restoration segment?”

  • 2

    “Neuralink projects reaching $1 billion in annual revenue by 2031. What are the critical milestones and potential bottlenecks, particularly regarding FDA commercial approval and scaling automated surgical procedures, that could impact this timeline?”

  • 3

    “With a Series E funding round completed and an active secondary market, how does Neuralink envision the timeline and potential mechanisms for a broader liquidity event for employees, and what are the company's current thoughts on managing dilution for future funding rounds?”

Community

Valuation Sentiment

Our model estimates -49% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.